ATRC News and Press, AtriCure Inc. From 02/28/19

AtriCure (NASDAQ: ATRC ) Q4 results ($M): Revenues: 52.9 (+14.8%); U.S.: 43.1 (+19.1%). More news on: AtriCure, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.21 misses by $0.04 ; GAAP EPS of -$0.09 beats by $0.08 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year Atri...

ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...

Endorsement complements the company’s ongoing commitment to physician education AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (S...

cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE ...

Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE ® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host ...

NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Textron Inc. (NYSE:TXT), Occidental Petroleum Corporation (NYSE:OXY), Atr...